Limits...
Infrequent Expression of the Cancer-Testis Antigen, PASD1, in Ovarian Cancer.

Khan G, Brooks SE, Mills KI, Guinn BA - Biomark Cancer (2015)

Bottom Line: If discovered early (Stage I), there is a 90% chance of five-year survival.We found that despite the positive staining of skin cancer, only one stage Ic ovarian cancer patient tissue expressed PASD1a and b at detectable levels.This may reflect the predominantly stage I ovarian cancer samples examined.

View Article: PubMed Central - PubMed

Affiliation: Department of Life Sciences, University of Bedfordshire, Park Square, Luton, Bedfordshire, UK.

ABSTRACT
Ovarian cancer is very treatable in the early stages of disease; however, it is usually detected in the later stages, at which time, treatment is no longer as effective. If discovered early (Stage I), there is a 90% chance of five-year survival. Therefore, it is imperative that early-stage biomarkers are identified to enhance the early detection of ovarian cancer. Cancer-testis antigens (CTAs), such as Per ARNT SIM (PAS) domain containing 1 (PASD1), are unique in that their expression is restricted to immunologically restricted sites, such as the testis and placenta, which do not express MHC class I, and cancer, making them ideally positioned to act as targets for immunotherapy as well as potential biomarkers for cancer detection where expressed. We examined the expression of PASD1a and b in a number of cell lines, as well as eight healthy ovary samples, eight normal adjacent ovarian tissues, and 191 ovarian cancer tissues, which were predominantly stage I (n = 164) and stage II (n = 14) disease. We found that despite the positive staining of skin cancer, only one stage Ic ovarian cancer patient tissue expressed PASD1a and b at detectable levels. This may reflect the predominantly stage I ovarian cancer samples examined. To examine the restriction of PASD1 expression, we examined endometrial tissue arrays and found no expression in 30 malignant tumor tissues, 23 cases of hyperplasia, or 16 normal endometrial tissues. Our study suggests that the search for a single cancer-testes antigen/biomarker that can detect early ovarian cancer must continue.

No MeSH data available.


Related in: MedlinePlus

PASD1 was found to be expressed in a number of human cancer cell lines. PASD1 expression was identified in K562, THIEL, HeLa, SW480, and Sk-Mel-28 cells; however, it was not found in the Ovcar3, Skov3, and A2780 ovarian cancer cell lines. Cells only and isotype controls were used as negative controls while no primary was used to determine background staining. Actin was used as a positive control. Red arrows indicate the brown deposition that identifies the subcellular localization of the immunolabeled target protein.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4539101&req=5

f1-bic-7-2015-031: PASD1 was found to be expressed in a number of human cancer cell lines. PASD1 expression was identified in K562, THIEL, HeLa, SW480, and Sk-Mel-28 cells; however, it was not found in the Ovcar3, Skov3, and A2780 ovarian cancer cell lines. Cells only and isotype controls were used as negative controls while no primary was used to determine background staining. Actin was used as a positive control. Red arrows indicate the brown deposition that identifies the subcellular localization of the immunolabeled target protein.

Mentions: Although the expression of PASD1 protein was detected by immunolabeling chronic myeloid leukemia, K562,17 multiple myeloma, THIEL (a gift from Prof. Diehl, University of Cologne, Germany), cervical cancer HeLa,18 colorectal cancer, SW480,19 and melanoma Sk-Mel-2820 cell line, PASD1 was not detected in the ovarian cancer cell lines: Skov3,21 Ovcar3,22 and A278023 (Fig. 1).16


Infrequent Expression of the Cancer-Testis Antigen, PASD1, in Ovarian Cancer.

Khan G, Brooks SE, Mills KI, Guinn BA - Biomark Cancer (2015)

PASD1 was found to be expressed in a number of human cancer cell lines. PASD1 expression was identified in K562, THIEL, HeLa, SW480, and Sk-Mel-28 cells; however, it was not found in the Ovcar3, Skov3, and A2780 ovarian cancer cell lines. Cells only and isotype controls were used as negative controls while no primary was used to determine background staining. Actin was used as a positive control. Red arrows indicate the brown deposition that identifies the subcellular localization of the immunolabeled target protein.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4539101&req=5

f1-bic-7-2015-031: PASD1 was found to be expressed in a number of human cancer cell lines. PASD1 expression was identified in K562, THIEL, HeLa, SW480, and Sk-Mel-28 cells; however, it was not found in the Ovcar3, Skov3, and A2780 ovarian cancer cell lines. Cells only and isotype controls were used as negative controls while no primary was used to determine background staining. Actin was used as a positive control. Red arrows indicate the brown deposition that identifies the subcellular localization of the immunolabeled target protein.
Mentions: Although the expression of PASD1 protein was detected by immunolabeling chronic myeloid leukemia, K562,17 multiple myeloma, THIEL (a gift from Prof. Diehl, University of Cologne, Germany), cervical cancer HeLa,18 colorectal cancer, SW480,19 and melanoma Sk-Mel-2820 cell line, PASD1 was not detected in the ovarian cancer cell lines: Skov3,21 Ovcar3,22 and A278023 (Fig. 1).16

Bottom Line: If discovered early (Stage I), there is a 90% chance of five-year survival.We found that despite the positive staining of skin cancer, only one stage Ic ovarian cancer patient tissue expressed PASD1a and b at detectable levels.This may reflect the predominantly stage I ovarian cancer samples examined.

View Article: PubMed Central - PubMed

Affiliation: Department of Life Sciences, University of Bedfordshire, Park Square, Luton, Bedfordshire, UK.

ABSTRACT
Ovarian cancer is very treatable in the early stages of disease; however, it is usually detected in the later stages, at which time, treatment is no longer as effective. If discovered early (Stage I), there is a 90% chance of five-year survival. Therefore, it is imperative that early-stage biomarkers are identified to enhance the early detection of ovarian cancer. Cancer-testis antigens (CTAs), such as Per ARNT SIM (PAS) domain containing 1 (PASD1), are unique in that their expression is restricted to immunologically restricted sites, such as the testis and placenta, which do not express MHC class I, and cancer, making them ideally positioned to act as targets for immunotherapy as well as potential biomarkers for cancer detection where expressed. We examined the expression of PASD1a and b in a number of cell lines, as well as eight healthy ovary samples, eight normal adjacent ovarian tissues, and 191 ovarian cancer tissues, which were predominantly stage I (n = 164) and stage II (n = 14) disease. We found that despite the positive staining of skin cancer, only one stage Ic ovarian cancer patient tissue expressed PASD1a and b at detectable levels. This may reflect the predominantly stage I ovarian cancer samples examined. To examine the restriction of PASD1 expression, we examined endometrial tissue arrays and found no expression in 30 malignant tumor tissues, 23 cases of hyperplasia, or 16 normal endometrial tissues. Our study suggests that the search for a single cancer-testes antigen/biomarker that can detect early ovarian cancer must continue.

No MeSH data available.


Related in: MedlinePlus